Thomas N Chase
Overview
Explore the profile of Thomas N Chase including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
624
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chase T, Al-Sabbagh A, Koga M, Clarence-Smith K
Clin Pharmacol Drug Dev
. 2024 Jan;
13(4):380-388.
PMID: 38176907
Levodopa/carbidopa remains the gold standard for treating Parkinson disease (PD), but chronic pulsatile administration contributes to motor complications. This Phase 1 study used a new immediate-release (IR) formulation of carbidopa/levodopa...
2.
Brown J, Park Y, Lee J, Chase T, Koga M, Borlongan C
Int J Mol Sci
. 2020 Apr;
21(8).
PMID: 32325813
Human mesenchymal stem cells have been explored for their application in cell-based therapies targeting stroke. Identifying cell lines that stand as safe, accessible, and effective for transplantation, while optimizing dosage,...
3.
Kaneko Y, Lee J, Tajiri N, Tuazon J, Lippert T, Russo E, et al.
Stem Cells Transl Med
. 2019 Nov;
9(2):203-220.
PMID: 31738023
The present study used in vitro and in vivo stroke models to demonstrate the safety, efficacy, and mechanism of action of adult human bone marrow-derived NCS-01 cells. Coculture with NCS-01...
4.
Chase T, Farlow M, Clarence-Smith K
Neurotherapeutics
. 2017 Feb;
14(2):405-416.
PMID: 28138837
Available cholinergic drugs for treating Alzheimer's disease (AD) provide modest symptomatic benefit. We hypothesized that co-administration of a peripheral anticholinergic to reduce dose-limiting adverse effects (AEs) would enable the safe/tolerable...
5.
Chase T
Neurotox Res
. 2010 May;
19(2):266-78.
PMID: 20473601
Apathy is an increasingly recognized concomitant of a broad range of central nervous system disorders. Nevertheless, its nosology, pathogenesis and therapy remain shrouded in confusion and controversy. As yet, there...
6.
Vanover K, Betz A, Weber S, Bibbiani F, Kielaite A, Weiner D, et al.
Pharmacol Biochem Behav
. 2008 Jun;
90(4):540-4.
PMID: 18534670
A potent 5-hydroxytryptamine (5-HT)2A receptor inverse agonist and antagonist, ACP-103 [N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1, active:salt)], was evaluated for its ability to reduce the primary motor symptom of tremor using tacrine-induced...
7.
Liang Z, Wang X, Li L, Wang Y, Chen R, Chuang D, et al.
J Neurosci Res
. 2007 Mar;
85(6):1295-309.
PMID: 17385714
Cell cycle reentry has been found during apoptosis of postmitotic neurons under certain pathological conditions. To evaluate whether nuclear factor-kappaB (NF-kappaB) activation promotes cell cycle entry and neuronal apoptosis, we...
8.
Liang Z, Li Y, Zhao X, Han R, Wang X, Wang Y, et al.
Brain Res
. 2007 Mar;
1145:190-203.
PMID: 17368433
To evaluate the contribution of NF-kappaB and the NF-kappaB target gene p53 to nigral dopaminergic neuron degeneration in rodent models of Parkinson's disease, time-course of dopaminergic neuron loss as well...
9.
Bara-Jimenez W, Dimitrova T, Sherzai A, Aksu M, Chase T
Mov Disord
. 2006 Jun;
21(9):1380-3.
PMID: 16758479
Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In...
10.
Liang Z, Wang X, Wang Y, Chuang D, DiFiglia M, Chase T, et al.
Neurobiol Dis
. 2005 Jun;
20(2):562-73.
PMID: 15922606
The present studies evaluated the potential contribution of Bcl-2, p53, and c-Myc to the differential vulnerability of striatal neurons to the excitotoxin quinolinic acid (QA). In normal rat striatum, Bcl-2...